Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karine Parain is active.

Publication


Featured researches published by Karine Parain.


Journal of Neurochemistry | 2003

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

Günter U. Höglinger; Jean Féger; Annick Prigent; Patrick P. Michel; Karine Parain; Pierre Champy; Merle Ruberg; Wolfgang H. Oertel; Etienne C. Hirsch

In Parkinsons disease, nigral dopaminergic neurones degenerate, whereas post‐synaptic striatal target neurones are spared. In some atypical parkinsonian syndromes, both nigral and striatal neurones degenerate. Reduced activity of complex I of the mitochondrial respiratory chain has been implicated in both conditions, but it remains unclear if this affects the whole organism or only the degenerating brain structures. We therefore investigated the differential vulnerability of various brain structures to generalized complex I inhibition. Male Lewis rats infused with rotenone, a lipophilic complex I inhibitor [2.5 mg/kg/day intraveneously (i.v.) for 28 days], were compared with vehicle‐infused controls. They showed reduced locomotor activity and loss of striatal dopaminergic fibres (54%), nigral dopaminergic neurones (28.5%), striatal serotoninergic fibres (34%), striatal DARPP‐32‐positive projection neurones (26.5%), striatal cholinergic interneurones (22.1%), cholinergic neurones in the pedunculopontine tegmental nucleus (23.7%) and noradrenergic neurones in the locus ceruleus (26.4%). Silver impregnation revealed pronounced degeneration in basal ganglia and brain stem nuclei, whereas the hippocampus, cerebellum and cerebral cortex were less affected. These data suggest that a generalized mitochondrial failure may be implicated in atypical parkinsonian syndromes but do not support the hypothesis that a generalized complex I inhibition results in the rather selective nigral lesion observed in Parkinsons disease.


Movement Disorders | 2001

Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice

Hélène Turmel; Andreas Hartmann; Karine Parain; Aicha Douhou; Anu Srinivasan; Yves Agid; Etienne C. Hirsch

In 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) models of Parkinsons disease (PD), dopaminergic (DA) neurons have been shown to die by apoptosis. Moreover, recent postmortem and in vitro results have indicated that apoptotic cell death induced by 1‐methyl‐4‐phenylpyridinium (MPP+) may be mediated by caspase‐3. To establish whether caspase‐3 activation may indeed play a role in an in vivo model of PD, we studied caspase‐3 activation in C57Bl/6 mice subchronically intoxicated with MPTP. We show that caspase‐3 activation peaks early, at days 1 and 2 after the end of MPTP intoxication. In contrast, pycnotic neurons persist until day 7 postintoxication, indicating that caspase‐3 activation is an early and transient phenomenon in apoptotic death of DA neurons. We further demonstrate that loss of tyrosine hydroxylase (TH) immunoreactivity in this model is indeed due to cell loss rather than to loss of TH protein expression. We conclude that mice subchronically intoxicated with MPTP represent a valid PD model to study and manipulate caspase activation in vivo.


Brain Research | 2003

Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin

Karine Parain; Céline Hapdey; Estelle Rousselet; Véronique Marchand; Bernard Dumery; Etienne C. Hirsch

Epidemiological studies have found a negative association between cigarette smoking and Parkinsons disease (PD). In order to analyze the putative neuroprotective effect of cigarette smoke and nicotine, one of its major constituents, we examined their effects in an animal model of PD provoked by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. Two groups of mice were chronically exposed to cigarette smoke (a low exposure subgroup and a high exposure subgroup; 5 exposures per day at 2-h intervals), two other groups received nicotine treatment (two doses tested 0.2 and 2 mg/kg, 5 injections i.p. per day at 2-h intervals) and one group placebo. On day 8 after the beginning of the treatment, 4 injections of MPTP hydrochloride (15 mg/kg, i.p., at 2-h intervals) or saline were administered to these animals. Nicotine and cotinine plasmatic concentration was quantified by the HPLC method, and degeneration of the nigrostriatal system was assessed by tyrosine hydroxylase (TH) immunohistochemistry. The loss of dopaminergic neurons induced by MPTP in the substantia nigra was significantly less severe in the chronic nicotine treatment groups (at 0.2 and 2 mg/kg) and the low exposure to cigarette smoke group than in the high exposure to cigarette smoke subgroup and the placebo treated subgroup. In contrast, no preservation of TH immunostaining of nerve terminals was observed in the striatum in any group. This suggests that nicotine and low exposure to cigarette smoke may have a neuroprotective effect on the dopaminergic nigrostriatal system by an as yet unknown mechanism.


Experimental Neurology | 2002

Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP

Estelle Rousselet; Jacques Callebert; Karine Parain; Chantal Joubert; Stéphane Hunot; Andreas Hartmann; Claude Jacque; Fernando Perez-Diaz; Charles Cohen-Salmon; Jean-Marie Launay; Etienne C. Hirsch

Abstract The loss of dopaminergic neurons in Parkinsons disease is associated with a glial reaction and the overproduction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α). TNF-α acts via two different receptors, TNFR1 and TNFR2, and is believed to have both a neuroprotective and a deleterious role for neurons. In order to analyze the putative role of TNF-α in parkinsonism, we compared the effect of the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice lacking TNFR1, TNFR2, or both receptors and in wild-type littermates. We show that MPTP does not affect spontaneous activity or anxiety in any of the groups and that it reduces motor activity on a rotarod in double knock out mice but not in mice lacking only one receptor. Postmortem analysis revealed no differences in the number of nigral dopaminergic neurons whatever the group. In contrast, striatal dopamine level was slightly decreased in double knock-out mice and more reduced by MPTP in this group than in the other groups of mice. In addition, dopamine turnover was significantly more increased in double knock out mice after MPTP injection. These data suggest that TNF-α does not participate in the death of dopaminergic neurons in parkinsonism but that it slightly alters dopamine metabolism or the survival of dopaminergic terminals by a mechanism involving both receptors.


Neurobiology of Disease | 2003

Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice

Estelle Rousselet; Chantal Joubert; Jacques Callebert; Karine Parain; Léon Tremblay; Gaël Orieux; Jean-Marie Launay; Charles Cohen-Salmon; Etienne C. Hirsch

Behavioral analyses of mice intoxicated by the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) have generated conflicting results. We therefore analyzed the relationship between behavioral changes, loss of monoamine levels, and loss of dopaminergic cell bodies in groups of mice intoxicated with acute or subchronic MPTP protocols. Despite a higher degree of neuronal loss in the mice intoxicated using subchronic protocols, dopamine loss was severe and homogeneous in the striatum in all groups. Dopamine levels were less severely reduced in the frontal cortex in the three groups of MPTP-intoxicated mice. Norepinephrine and serotonin levels in the striatum were decreased only in the mice intoxicated with the acute protocol. The most surprising result was that the mice intoxicated with the subchronic protocols were more active than the saline-treated mice. As reported in rats with dopamine depletion in the prefrontal cortex, the hyperactivity observed in our mice could be due to the reduced dopamine levels detected in this structure.


The Journal of Comparative Neurology | 2002

Three-dimensional cartography of functional territories in the human striatopallidal complex by using calbindin immunoreactivity

Carine Karachi; Chantal François; Karine Parain; Eric Bardinet; Dominique Tandé; Etienne C. Hirsch; Jérôme Yelnik

This anatomic study presents an analysis of the distribution of calbindin immunohistochemistry in the human striatopallidal complex. Entire brains were sectioned perpendicularly to the mid‐commissural line into 70‐μm‐thick sections. Every tenth section was immunostained for calbindin. Calbindin labeling exhibited a gradient on the basis of which three different regions were defined: poorly labeled, strongly labeled, and intermediate. Corresponding contours were traced in individual sections and reformatted as three‐dimensional structures. The poorly labeled region corresponded to the dorsal part of the striatum and to the central part of the pallidum. The strongly labeled region included the ventral part of the striatum, the subcommissural part of the external pallidum but also the adjacent portion of its suscommissural part, and the anterior pole of the internal pallidum. The intermediate region was located between the poorly and strongly labeled regions. As axonal tracing and immunohistochemical studies in monkeys show a similar pattern, poorly, intermediate, and strongly labeled regions were considered as the sensorimotor, associative, and limbic territories of the human striatopallidal complex, respectively. However, the boundaries between these territories were not sharp but formed gradients of labeling, which suggests overlapping between adjacent territories. Similarly, the ventral boundary of the striatopallidal complex was blurred, suggesting a structural intermingling with the substantia innominata. This three‐dimensional partitioning of the human striatopallidal complex could help to define functional targets for high‐frequency stimulation with greater accuracy and help to identify new stimulation sites. J. Comp. Neurol. 450:122–134, 2002.


medical image computing and computer assisted intervention | 2002

Co-registration of Histological, Optical and MR Data of the Human Brain

Eric Bardinet; Sebastien Ourselin; Didier Dormont; Grégoire Malandain; Dominique Tandé; Karine Parain; Nicholas Ayache; Jérôme Yelnik

In order to allow accurate pre-operative localisation of functional targets in functional neurosurgery, we aim at constructing a three dimensional registrable cartography of the basal ganglia, based on histology. For doing this, a post mortem MR study was conducted on a cadavers head, and the brain was then extracted and processed for histology. The post mortem MR image will allow to report the cartography on the patients anatomy, by its registration with the patients MR image. In this paper, we focus on the problem of co-registering the histological and post mortem MR data of the same subject. First, realignment of the histological sections into a reliable three dimensional volume is performed. Then the reconstructed volume is registered with the post mortem MR image. To insure three dimensional integrity of the histological reconstructed volume, a reference volume is first constructed from photographs of the unstained surface of the frozen brain. This reference is then used as an intermediate volume for, on the one hand, independant alignment of each histological section with its corresponding optical section and on the other hand, three dimensional registration with the post mortem MR image.


medical image computing and computer assisted intervention | 2001

Fusion of Histological Sections and MR Images: Towards the Construction of an Atlas of the Human Basal Ganglia

Sebastien Ourselin; Eric Bardinet; Didier Dormont; Grégoire Malandain; Alexis Roche; Nicholas Ayache; Dominique Tandé; Karine Parain; Jérôme Yelnik

In neurosurgery, localisation of deep brain structures is a crucial issue, which can be assisted by a 3-dimensional brain atlases. Our goal is to build such an atlas by fusing histological data with a 3D MR image of the same subject. This requires two steps: first a 2D realignment of the histological sections in order to obtain a three-dimensional block, then a 3D registration between this reconstructed block and the MR image. Both steps are based on the same robust registration algorithm.


Brain Research | 2001

Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice.

Karine Parain; Véronique Marchand; Bernard Dumery; Etienne C. Hirsch

In order to analyze the putative neuroprotective role of nicotine and cotinine in parkinsonian syndromes, these two compounds were administered in male C57Bl6 mice for 4 weeks. On day 8, four injections of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) were administered. MPTP intoxication induced a 50% loss of dopaminergic neurons in the substantia nigra and a 45% reduction in dopaminergic fibers in the striatum. Administration of cotinine did not affect MPTP toxicity in the nigrostriatal system but chronic nicotine treatment showed a slight protection (15%) of nigrostriatal dopaminergic neurons against MPTP.


Journal of Neurochemistry | 2003

Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice

Isabelle Gourfinkel-An; Karine Parain; Andreas Hartmann; Laura Mangiarini; Alexis Brice; Gillian P. Bates; Etienne C. Hirsch

Huntingtons disease is an autosomal dominant disorder with degeneration of medium size striatal neurones. As the disease evolves, other neuronal populations are also progressively affected. A transgenic mouse model of the disease (R6/2) that expresses exon 1 of the human Huntington gene with approximately 150 CAG repeats has been developed, but GABA concentrations are reported to be normal in the striatum of these animals. In the present study, we analysed the status of GABAergic systems by means of glutamic acid decarboxylase (GAD)67 mRNA in situ hybridization in the brain of R6/2 transgenic mice and wild‐type littermates. We show that GAD67 expression is normal in the striatum, cerebellum and septum but decreased in the frontal cortex, parietal cortex, globus pallidus, entopeduncular nucleus and substantia nigra pars reticulata of R6/2 mice. These data, which may, in part, account for the behavioural changes seen in these animals, indicate that at 12.5 weeks of age the pathological features seen in the mice differ from those seen in humans with Huntingtons disease.

Collaboration


Dive into the Karine Parain's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicholas Ayache

French Institute for Research in Computer Science and Automation

View shared research outputs
Top Co-Authors

Avatar

Charles Cohen-Salmon

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge